<DOC>
	<DOCNO>NCT01967160</DOCNO>
	<brief_summary>A non-interventional study assess incident rate Osteonecrosis Jaw Infections lead hospitalization Cancer patient treat XGEVA™ Sweden , Denmark Norway .</brief_summary>
	<brief_title>Osteonecrosis Jaw ( ONJ ) Infection Among Nordic Cancer Patients Treated With XGEVA™ Zoledronic Acid</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Osteonecrosis</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Denosumab</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>≥ 18 year old diagnose cancer subsequent cancer diagnosis , initiate cancerrelated antiresorptive treatment treatment cohort identification period XGEVA zoledronic acid switch XGEVA cancerrelated treatment oral IV bisphosphonates dose indicate SRE prevention le 2 year duration ( ≤ 24 IV infusion ≤ 24 monthly oral prescription ) history radiation treatment head neck cancer subject 's potential index date hypercalcemia malignancy sole indication treatment antiresorptive agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>